EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Track record

Tools

  • Compare
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›IPAR

IPAR

INTERPARFUMS INC

Next earnings Jul 21, 2026 · consensus $0.98 EPS, $342M rev

Last earnings +2.2% on 2026-05-05

Hold
$107.97
▲ +3.46%
$107.97▼ -15.56%
over 1Y
L $77.51EODHDH $133.95
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.5%
1W+10.5%
1M+14.4%
3M+20.2%
YTD+28.5%
1Y-15.6%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Hold
Quality
B
Valuation
Overvalued
Filings
Flagged
Hold
Conviction
Horizon
Long (>12mo)
12-mo target
$•••
Street · 11 analysts
Buy

Quality licensed-fragrance compounder at a fair price — durable brand portfolio, but growth has decelerated sharply and the model is structurally dependent on third-party licenses.

The read

Middling fundamentals and a rich price (~35% above fair value) leave little margin of safety — a wait-and-see.

Interparfums is a high-quality, capital-light operator in prestige fragrance with a diversified license portfolio (Jimmy Choo 17%, Coach 15%, Montblanc 15%, GUESS 12%, Lacoste 7%, DKNY 7%, Ferragamo 4%) distributed in 120+ countries. The fundamentals are clean: 63.6% gross margin, 18.2% operating margin, 19.1% ROE, and operating cash flow of $215M comfortably covering $24.4M of capex and $103M of dividends. The balance sheet is sound with $881M of equity against $176M of total debt, and retained earnings grew 8.6% to $829M. This is the profile of a steady compounder, and at 19.7x earnings and 2.2x sales, the market is paying a reasonable — not cheap — multiple for it.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$880M$1.09B$1.32B$1.45B$1.49B
Gross profit$557M$694M$839M$927M$947M
Operating income$148M$194M$251M$275M$270M
Net income$87.4M$121M$153M$164M$168M
Diluted EPS$2.75$3.78$4.75$5.12$5.24
Net margin9.9%11.1%11.6%11.3%11.3%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value-$156B
EV / EBITDA-527.6
EV / Sales-104.8
EV / FCF-818.8
P / FCF18.2
PEG (trailing)8.41
Earnings yield4.9%
FCF yield5.5%

Quality & risk

ROIC (est.)20.2%
Free cash flow$190M
Total debt$176M
Net cash$159B
Piotroski F-Score6/9

Capital returns

Buyback yield0.0%
Dividend yield (est.)3.0%
Shareholder yield3.0%
Shares Δ YoY-0.2%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Recent disclosure tone has skewed negative — read the flagged items.
  1. 8-K Auditor change2026-05-13

    Change in certifying accountant disclosed; auditor transition adds short-term oversight risk.

  2. 8-K Earnings results2026-05-05

    Q1 2026 10-Q filed; details Q1 operations as growth moderates from prior years.

  3. 10-Q Quarterly report2026-05-05

    Q1 2026 10-Q filed; details Q1 operations as growth moderates from prior years.

  4. 8-K Earnings results2026-04-21

    Pre-announced Q1 2026 preliminary sales/financial update ahead of full earnings.

  5. 10-K Annual report2026-03-10

    FY2025 10-K: rev $1.49B (+2.5%), op income -1.6%, equity +18%; growth sharply slowing.

  6. NT 10-K Late filing notice2026-03-03

    NT 10-K: notified late filing of FY2025 annual report, raising near-term reporting concern.

  7. 8-K Earnings results2026-02-24

    FY2025 earnings released: revenue +2.5% to $1.49B, EPS $5.24, growth markedly decelerating.

  8. 8-K Reg FD disclosure2026-01-29

    Companion 8-K (likely dividend or guidance update) issued alongside prelim-sales release.

  9. 8-K Reg FD disclosure2026-01-29

    Companion 8-K (likely dividend or guidance update) issued alongside prelim-sales release.

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-05-082026-05-13open ↗8-KPeriod ending 2026-05-052026-05-05open ↗10-QPeriod ending 2026-03-312026-05-05open ↗8-KPeriod ending 2026-04-212026-04-21open ↗4Period ending 2026-04-022026-04-03open ↗144Filing2026-04-02open ↗SCHEDULE 13G/AFiling2026-03-27open ↗10-KPeriod ending 2025-12-312026-03-10open ↗NT 10-KPeriod ending 2026-03-032026-03-03open ↗8-KPeriod ending 2026-02-242026-02-24open ↗8-KPeriod ending 2026-01-282026-01-29open ↗8-KPeriod ending 2026-01-282026-01-29open ↗

Quality score

B
ValueGrowthProfitHealthMom.
ValueB-
GrowthC+
ProfitabilityA-
Financial healthA-
Momentum—
  • ✓Revenue growing year-over-year
  • ✓Profitable (positive net income)
  • ✓Net margin above 10%
  • ✓Return on equity above 15%
  • ✓P/E below 25

Fair value est.

$70.36

Overvalued -35% vs price

cheapfair valueexpensive

Modified Graham: EPS $5.24 × (8.5 + 1.5 × 2.5% growth) × 1.10 quality = 13.4× multiple. An estimate, not a price target.

Revenue
$1.49B
+2.5% YoY
Net margin
11.3%
ROE
19.1%
P/E
20.6

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$1.49B+2.5%
Net income$168M+2.5%
Gross profit$947M+2.1%
Operating income$270M-1.6%
Diluted EPS$5.24+2.3%
Cash & equivalents$160B+93966.5%
Total assets$1.59B+12.3%
Stockholders' equity$881M+18.2%
Gross: 63.6%Op.: 18.2%

Frequently asked

Is INTERPARFUMS INC (IPAR) a buy?
IPAR currently carries a Hold rating with 4/5 conviction, derived from its latest SEC filings. Quality licensed-fragrance compounder at a fair price — durable brand portfolio, but growth has decelerated sharply and the model is structurally dependent on third-party licenses.
What is IPAR's fair value?
A Modified-Graham model based on IPAR's SEC fundamentals estimates a fair value of about $70.36. It is an estimate from reported earnings, not a price target.
Is IPAR overvalued or undervalued?
Against a Modified-Graham fair-value estimate, IPAR currently appears overvalued relative to its SEC-grounded earnings power.
What is INTERPARFUMS INC's quality score?
IPAR scores 72.90196078431372/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0000822663, latest 10-Q filed 2026-05-05) · EODHD · analysis by claude-code · as of 6/25/2026, 1:46:59 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 0 open-market buys · 1 sale

2026-04-02
MADAR JEAN
CEO
Sell20.0K @ $91.02$1.82M
2026-01-23
HEILBRONN FRANCOIS
Director
Exercise1.50K @ $62.18$93.3K
2026-01-22
Harrison Gilbert
Director
Exercise1.50K @ $62.18$93.3K
2026-01-22
BENSOUSSAN TORRES ROBERT
Director
Exercise1.50K @ $62.18$93.3K

Dividends

Quarterly
Yield (TTM)
3.0%
Annual / share
$3.20
Last ex-date
2026-06-15
Last amount
$0.80
ex 2026-06-15paid 2026-06-30$0.80
ex 2026-03-16paid 2026-03-31$0.80
ex 2025-12-15paid 2025-12-31$0.80
ex 2025-09-15paid 2025-09-30$0.80
ex 2025-06-13paid 2025-06-30$0.80
ex 2025-03-14paid 2025-03-28$0.80

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Earnings history

beat/miss · move
2026-05-05Beat +10.0% est▲ +2.20%8-K ↗
2026-04-21Beat +10.0% est▼ -2.87%8-K ↗
2026-02-24Beat +14.5% est▲ +1.25%8-K ↗
2026-01-21Beat +14.5% est▲ +1.29%8-K ↗
2025-11-05Beat +2.7% est▲ +1.86%8-K ↗
2025-10-20Beat +2.7% est▲ +0.47%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
How to Play Ulta Beauty Stock After a 24% Plunge in 6 Months?Bullish
finance.yahoo.com· 2026-06-24
A Look Back at Personal Care Stocks’ Q1 Earnings: e.l.f. Beauty (NYSE:ELF) Vs The Rest Of The PackBullish
finance.yahoo.com· 2026-06-22
Ulta Beauty's Fragrance Push: Is This a Winning Growth Formula?Bullish
finance.yahoo.com· 2026-06-19
How Ulta Beauty Is Expanding Beyond Traditional Beauty Retail?Bullish
finance.yahoo.com· 2026-06-16
Ulta Beauty's Omnichannel Strategy Continues to Deliver Strong ResultsBullish
finance.yahoo.com· 2026-06-15
1 Russell 2000 Stock to Consider Right Now and 2 Facing ChallengesBullish
finance.yahoo.com· 2026-06-12

Vs tracked universe

compare →

1044 tracked peers · median

EDGAR Score73 vs 67
Revenue growth2.5% vs 7.1%
Net margin11.3% vs 10.5%
Return on equity19.1% vs 12.3%
P/E20.6 vs 25.5

News sentiment

EODHD · 20d
Bullish
+0.18
vs typical · 29 articles

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.